Chu DK, et al. - Since aspirin desensitization is increasingly recommended to treat aspirin-exacerbated respiratory disease (AERD), researchers tested the safety and effectiveness of aspirin desensitization (mean daily dose 800 mg) in patients (n = 233) with AERD. From inception to January 5, 2019, MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, and World Health Organization (WHO) International Clinical Trials Registry Platform were searched. According to this systematic review and meta-analysis, moderate-certainty and high-certainty evidence in patients with AERD indicates that aspirin desensitization meaningfully decreases symptoms of rhinosinusitis and improves quality of life, but results in a significant increase in adverse events such as major bleeding, gastritis, asthma exacerbation, or rash causing drug discontinuation.